Identification and Visualization of Kinase-Specific Subpockets
暂无分享,去创建一个
Friedrich Rippmann | Sameh Eid | Simone Fulle | Samo Turk | Andrea Volkamer | S. Turk | Sameh Eid | F. Rippmann | S. Fulle | Andrea Volkamer
[1] Friedrich Rippmann,et al. TRAPP: A Tool for Analysis of Transient Binding Pockets in Proteins , 2013, J. Chem. Inf. Model..
[2] Isidro Cortes-Ciriano,et al. Proteochemometric modelling coupled to in silico target prediction: an integrated approach for the simultaneous prediction of polypharmacology and binding affinity/potency of small molecules , 2015, Journal of Cheminformatics.
[3] Matthias Rarey,et al. Exploiting structural information for drug-target assessment. , 2014, Future medicinal chemistry.
[4] J. Kissil,et al. Recent advances in the development of p21-activated kinase inhibitors , 2012, Cellular logistics.
[5] Matthias Rarey,et al. Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets , 2010, J. Chem. Inf. Model..
[6] J. Chernoff,et al. PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.
[7] P. Prusis,et al. Visually Interpretable Models of Kinase Selectivity Related Features Derived from Field-Based Proteochemometrics , 2013, J. Chem. Inf. Model..
[8] Gerhard Klebe,et al. Integrated Approach Using Protein and Ligand Information to Analyze Selectivity‐ and Affinity‐Determining Features of Carbonic Anhydrase Isozymes , 2006, ChemMedChem.
[9] Adam R. Johnson,et al. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. , 2014, Journal of medicinal chemistry.
[10] K. Wilson,et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.
[11] K. Hoeflich,et al. Inhibitors of p21-activated kinases (PAKs). , 2015, Journal of medicinal chemistry.
[12] Jianwen A. Feng,et al. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors. , 2014, Journal of medicinal chemistry.
[13] S. Licciulli,et al. FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas* , 2013, The Journal of Biological Chemistry.
[14] Joost C. M. Uitdehaag,et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets , 2012, British journal of pharmacology.
[15] D. Bouzida,et al. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. , 2012, Journal of medicinal chemistry.
[16] P. Bamborough. System-based drug discovery within the human kinome , 2012, Expert opinion on drug discovery.
[17] Stephen R. Johnson,et al. 3D Matched Pairs: Integrating Ligand- and Structure-Based Knowledge for Ligand Design and Receptor Annotation , 2013, J. Chem. Inf. Model..
[18] Andreas Bender,et al. Analyzing Multitarget Activity Landscapes Using Protein-Ligand Interaction Fingerprints: Interaction Cliffs , 2015, J. Chem. Inf. Model..
[19] Lydia Siragusa,et al. BioGPS Descriptors for Rational Engineering of Enzyme Promiscuity and Structure Based Bioinformatic Analysis , 2014, PloS one.
[20] S. Knapp,et al. The (un)targeted cancer kinome. , 2010, Nature chemical biology.
[21] S. Tonegawa,et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 , 2013, Proceedings of the National Academy of Sciences.
[22] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[23] Nathanael Weill,et al. Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..
[24] Matthias Rarey,et al. Fast Protein Binding Site Comparison via an Index-Based Screening Technology , 2013, J. Chem. Inf. Model..
[25] G. Klebe,et al. A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.
[26] D. Fabbro,et al. Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor. , 2015, ACS medicinal chemistry letters.
[27] G. Cole,et al. PAK in Alzheimer disease, Huntington disease and X-linked mental retardation , 2012, Cellular logistics.
[28] E. Lionta,et al. Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.
[29] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[30] Yu-Wei Chang,et al. An enriched structural kinase database to enable kinome‐wide structure‐based analyses and drug discovery , 2010, Protein science : a publication of the Protein Society.
[31] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[32] L. Berg,et al. Tec kinases in T cell and mast cell signaling. , 2007, Advances in immunology.
[33] F. Javier Luque,et al. MDpocket: open-source cavity detection and characterization on molecular dynamics trajectories , 2011, Bioinform..
[34] Friedrich Rippmann,et al. Pocketome of Human Kinases: Prioritizing the ATP Binding Sites of (Yet) Untapped Protein Kinases for Drug Discovery , 2015, J. Chem. Inf. Model..
[35] Paolo Benedetti,et al. FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation using the DUD Data Set , 2010, J. Chem. Inf. Model..
[36] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[37] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[38] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[39] H. Wolfson,et al. Recognition of Functional Sites in Protein Structures☆ , 2004, Journal of Molecular Biology.
[40] W. Peti,et al. Molecular basis of MAP kinase regulation , 2013, Protein science : a publication of the Protein Society.
[41] J. Boehm,et al. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.
[42] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[43] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[44] Anupama E. Gururaj,et al. p21-activated kinases in cancer , 2006, Nature Reviews Cancer.
[45] B. Tidor,et al. Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.
[46] Daniel Kuhn,et al. Combining Global and Local Measures for Structure-Based Druggability Predictions , 2012, J. Chem. Inf. Model..
[47] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[48] J. Bajorath,et al. Systematic Assessment of Molecular Selectivity at the Level of Targets, Bioactive Compounds, and Structural Analogues , 2016, ChemMedChem.
[49] Daniel Moser,et al. VAMMPIRE: a matched molecular pairs database for structure-based drug design and optimization. , 2013, Journal of medicinal chemistry.
[50] G. Klebe,et al. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.
[51] Gabriele Cruciani,et al. BioGPS: Navigating biological space to predict polypharmacology, off‐targeting, and selectivity , 2015, Proteins.
[52] E. A. O'neill,et al. Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.
[53] M Hendlich,et al. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.
[54] R. Guha,et al. Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.
[55] Chris de Graaf,et al. KLIFS: a structural kinase-ligand interaction database , 2015, Nucleic Acids Res..
[56] J. Field,et al. PAK signaling in cancer , 2012, Cellular logistics.
[57] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[58] H. Oki,et al. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. , 2012, Journal of medicinal chemistry.
[59] P. LoRusso,et al. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology , 2008, Expert opinion on investigational drugs.
[60] Eyke Hüllermeier,et al. Functional Classification of Protein Kinase Binding Sites Using Cavbase , 2007, ChemMedChem.
[61] A. Bender,et al. Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.
[62] R C Wade,et al. Identifying targets for bioreductive agents: using GRID to predict selective binding regions of proteins. , 1989, Journal of molecular graphics.
[63] I. Aliagas,et al. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors. , 2015, Journal of medicinal chemistry.
[64] H. Matter,et al. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.
[65] D. Knighton,et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth , 2010, Proceedings of the National Academy of Sciences.
[66] G. Parmigiani,et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.
[67] E. Goldsmith,et al. Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.
[68] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.
[69] Christoph Steinbeck,et al. Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials. , 2006, Journal of molecular graphics & modelling.
[70] G. Kéri,et al. Rational Drug Design of Kinase Inhibitors for Signal Transduction Therapy , 2011 .
[71] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[72] Tomoyasu Ishikawa,et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.
[73] Yan Yin,et al. Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations. , 2015, Bioorganic & medicinal chemistry.
[74] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[75] M. Baccarini,et al. Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.
[76] G. Scapin. Protein kinase inhibition: different approaches to selective inhibitor design. , 2006, Current drug targets.